Navigation Links
Monoclonal Antibody with Xencor's High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia
Date:4/26/2013

MONROVIA, Calif., April 26, 2013 /PRNewswire/ -- Xencor announced today that MorphoSys AG has dosed the first patient in a Phase 2 clinical trial of MOR208 in B-cell acute lymphoblastic leukemia (B-ALL). MOR208 is a potent anti-CD19 monoclonal antibody Fc optimized for high cytotoxic function for which MorphoSys licensed exclusive worldwide rights from Xencor in 2010. The dosing of the first patient in the study triggers an undisclosed milestone payment to Xencor.

The US-based study is an open-label, multicenter, single-arm clinical trial designed to assess the efficacy of MOR208 in patients suffering from relapsed or refractory B-ALL. Secondary outcome measures include response duration, safety and pharmacokinetics of MOR208. In total, 30 patients are planned to be enrolled. More information on the trial can be found by searching for MOR208 at www.clinicaltrials.gov.

"Preclinical and early clinical studies of MOR208 have shown promising anti-tumor activity and supported this additional study in ALL as well as another study in Non Hodgkin's Lymphoma which is expected to start shortly," said Bassil Dahiyat , Ph.D., Chief Executive Officer of Xencor. "Xencor monoclonal antibody candidates continue to advance in clinical development and showcase the value of our XmAb® Fc technology."

MOR208 has shown in a Phase 1/2a trial encouraging signs of preliminary anti-tumor activity and an acceptable safety and tolerability profile in patients with high-risk, heavily pretreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). In addition to the phase 2 trial in B-ALL MorphoSys is about to start a second Phase 2 trial in Non-Hodgkin's Lymphoma (NHL).

B-cell malignancies, such as B-ALL, NHL and CLL affect more than one hundred and fifty thousand patients in the seven major markets each year. The target molecule CD19
'/>"/>

SOURCE Xencor
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology news :

1. Clinical trial for rabies monoclonal antibody
2. New monoclonal antibody developed that can target proteins inside cancer cells
3. Dual action polyclonal antibody may offer more effective, safer protection against osteoporosis
4. Flu antibody’s one-handed grab may boost effort toward universal vaccine, new therapies
5. International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering
6. Labor der Zukunft -- Tomorrows laboratory technology
7. The future of plant science - a technology perspective
8. The future of plant science a technology perspective
9. Ultracold matter technology from CU and SRI International licensed to Boulders ColdQuanta
10. UF researchers look for ways to make an emerging technology safe for environment
11. Breast cancer risk gene discovery fast tracked by new technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... NEW YORK , Aug. 27, 2014 /PRNewswire/ ... report is available in its catalogue: ... http://www.reportlinker.com/p02316674/Law-Enforcement-Biometrics-Market-in-North-America-2014-2018.html ... to assess individuals on the basis of their ... and identification of both physiological traits such as ...
(Date:8/27/2014)... PITTSBURGHLearning a new skill is easier when it is ... a trained pianist might learn a new melody more ... , Neural engineers from the Center for the Neural ... of Pittsburgh and Carnegie Mellon Universityhave discovered a fundamental ... happens. Published as the cover story in the Aug. ...
(Date:8/27/2014)... the greatest risk to Europe based upon a proxy ... researchers using a ,big data, approach to scientific research. ... and Global Health ranked the top 100 pathogens affecting ... a system which, they believe, will help governments across ... of infectious diseases, including as a result of climate ...
Breaking Biology News(10 mins):Law Enforcement Biometrics Market in North America 2014-2018 2Law Enforcement Biometrics Market in North America 2014-2018 3Law Enforcement Biometrics Market in North America 2014-2018 4Law Enforcement Biometrics Market in North America 2014-2018 5Pitt and Carnegie Mellon engineers discover why learning can be difficult 2Pitt and Carnegie Mellon engineers discover why learning can be difficult 3Big data approach identifies Europe's most dangerous human and domestic animal pathogens 2
... as 50 percent of all human protein-coding genes are ... onset and progression of cancer, others can actually suppress ... cancer therapy. They can also serve as potential biomarkers ... Cancer Biomarkers , investigators report on non-coding miRNAs ...
... have created stunning images of the branching patterns of individual ... eLife on Dec. 18, details the arrangement of ... branching patterns define ten distinct groups that, the researchers say, ... could hold clues for pain management and other areas of ...
... inexpensive new source of a widely used chemical for plastics, ... Succinic acid, traditionally drawn from petroleum, is one focus of ... 2004, the Department of Energy named succinic acid one of ... biological means and turned into high-value materials. Several ...
Cached Biology News:MicroRNAs present exciting opportunities for cancer therapy and diagnosis 2MicroRNAs present exciting opportunities for cancer therapy and diagnosis 3Why our backs can't read braille 2Why our backs can't read braille 3Soybeans a source of valuable chemical 2
(Date:8/27/2014)... DUBLIN , Aug. 27, 2014 ... "Global Stable Isotope Ratio Mass Spectrometer Industry Report ... The Global Stable Isotope Ratio Mass Spectrometer Industry Report ... current state of the global isotope ratio mass spectrometer ... of the industry including definitions, classifications, applications and industry ...
(Date:8/27/2014)... Boca Raton, FL (PRWEB) August 27, 2014 ... that are applied through the use of a handheld ... consumers across the United States. , The brand ... care unit. BIOEQUA researchers were surprised to learn that ... to be made extremely small and delivered directly to ...
(Date:8/27/2014)... 2014 WriteResult, LLC – a premier ... again shown superiority when it comes to meeting the ... ePRO portion of their most recent study closeout on-time ... chose WriteResult’s digital writing platform to collect Patient Reported ... to complete drew data from a number of assessments ...
(Date:8/26/2014)... San Diego, CA, and Bellingham, WA (PRWEB) August ... nanoscience and optical engineering, visions for next-generation wearable ... Light 2015 among numerous highlights at this year’s ... in the San Diego, California, Convention Center. More ... suppliers last week attended conferences, courses, an exhibition, ...
Breaking Biology Technology:Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 2BIOEQUA'S EQUA ESSENTIAL Product Line Redefines Skin Care & Now Available in America 2A Perfect Record: WriteResult Maintains a 100% On-Time ePRO Record with Latest Irritable Bowel (IBS) Study Data Lock 2Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 2Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 3Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 4
... attract the presence of major pharmaceutical companies from out ... own environment, said a panel assembled Monday night by ... building the future today in Wisconsin has to do ... CEO Irene Hrusovsky. , ,Woody Hydrick, a senior consultant ...
... the next ten years, according to a proposal that has ... Senate for a vote this month. State Senator Joe Leibham, ... that would be regulated similarly to airports. , ,Leibhams bill, ... private space travel in the area, receive any potential federal ...
... the lineup for DEMO 2006 nears, Ive had plenty of ... launch. , ,Does a product in "beta" variously defined ... qualify as launch-ready? Must I have customers in the queue ... a shipping product that we've only talked about with our ...
Cached Biology Technology:Panel stresses drawing outside biotech firms to state 2Space port could open in Sheboygan in next 10 years 2Space port could open in Sheboygan in next 10 years 3When do you go from "beta" to "product launch"? 2When do you go from "beta" to "product launch"? 3
... in heart tissues, and is produced ... conditions. Treatment of cells with ... TIMP-4 in some cell types, but ... require concentration of cell culture media ...
Goat polyclonal to HSPC150 ( Abpromise for all tested applications). entrezGeneID: 29089...
Anti-MMP-13 Collagenase-3, amino terminal end of active enzyme; rabbit host...
...
Biology Products: